Skip to content

Rev Neurol. 2021 Oct 16;73(8):275-281. doi: 10.33588/rn.7308.2021261. ABSTRACT INTRODUCTION: Patients with CIDP respond adequately to steroid therapy and intravenous immunoglobulin (IVIG). However, few patients have access to IVIG in developing countries. Little information exists about the clinical response to steroid therapy in Latin American countries. OBJECTIVE: to describe the long-term functional clinical response (24 months) […] Read More

The public are being reminded to come forward for their flu jab to maximise their protection ahead of winter. Health officials are worried because this will be the first winter Covid and flu circulate fully at the same time. Research shows those infected with both viruses are more than twice as likely to die as […] Read More

The government has agreed to end the requirement for shielding guidance for people previously considered to be clinically extremely vulnerable. People previously considered to be clinically extremely vulnerable will not be advised to shield again, as the government agrees to end the requirement for centralised guidance for these groups following expert clinical advice. The closure […] Read More

Posted on

The September 200 Club Draw winning numbers were: Number 78 – £39.67 Number 19 – £19.83 Number 116 – £19.83 New members sign up before October 13th to be in the next draw!

Acute inflammatory demyelinating polyneuropathy (AIDP), characterized by the autoimmune destruction of Schwann cells with resultant myelin degradation, is the most common subtype of Guillain-Barré Syndrome (GBS). GBS encompasses a myriad of autoimmune polyradiculoneuropathies, typically following an antecedent infectious process. Symptom onset is typically 1-3 weeks following an upper respiratory or gastrointestinal illness and consists of […] Read More

Should someone who has had GBS unrelated to COVID-19 vaccination have a COVID-19 vaccination? Yes, they should be vaccinated as recommended for their age and risk group. A causal link between COVID-19 vaccination and GBS has not been proven and there is no evidence of a higher rate of reporting of GBS following COVID-19 vaccination in individuals who have previously had GBS. Hence, the balance of risk benefit is in […] Read More

200 Club August Draw

Posted on

The August 200 Club Draw winning numbers were: Number 54 – £39 Number 108 – £19.50 Number 11 – £19.50 New members sign up before September 8th to be in the next draw!  

We would like to inform you that we have updated the product information for Vaxzevria (formerly known as COVID-19 Vaccine AstraZeneca).   Following a review of the available data, a precautionary warning about Guillain-Barré Syndrome (GBS) has been included in the Summary of Product Characteristics and Patient Information Leaflet for Vaxzevria. This is to help […] Read More

Latest update on the vaccine from our Medical Advisors There has been no rise in cases of GBS in January to March 2021.  If vaccines caused GBS at a frequency of 1:100000 or more, we would have seen a doubling in cases. If the rate were 1 per million doses, we might only just see […] Read More

Vaccine Roll Outs: Tragedy and Triump‪h‬ Dan Snow’s History Hit Paul Offit is on the US Food and Drug Administration’s advisory panel on vaccines. He talked Dan through the history of massive public vaccination programmes in the US, starting with the unprecedented campaign against Polio in 1955. During that vaccination 200,000 children were a form […] Read More